Technical Data - Stock Traders Daily
| BCRX Stock | USD 7.83 0.03 0.38% |
Slightly above 53% of BioCryst Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that many traders are impartial. BioCryst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BioCryst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
BioCryst |
Technical Data Stock Traders Daily
Read at news.google.com
 |
BioCryst Pharmaceuticals Fundamental Analysis
We analyze BioCryst Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
BioCryst Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
BioCryst Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioCryst Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
BioCryst Pharmaceuticals Related Equities
| MCRB | Seres Therapeutics | 4.11 | ||||
| ATRA | Atara Biotherapeutics | 3.93 | ||||
| XFOR | X4 Pharmaceuticals | 3.85 | ||||
| CGTX | Cognition Therapeutics | 2.27 | ||||
| AXSM | Axsome Therapeutics | 2.19 | ||||
| APLS | Apellis Pharmaceuticals | 2.06 | ||||
| AVXL | Anavex Life | 1.92 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.03 | ||||
| DAWN | Day One | 0.86 | ||||
| PDSB | PDS Biotechnology | 0.81 | ||||
| KZR | Kezar Life | 0.77 | ||||
| VKTX | Viking Therapeutics | 0.80 | ||||
| BPMC | Blueprint Medicines | 1.09 | ||||
| TGTX | TG Therapeutics | 1.45 | ||||
| SAVA | Cassava Sciences | 2.86 | ||||
| IMUX | Immunic | 4.00 | ||||
| INMB | INmune Bio | 4.14 | ||||
| BIVI | Biovie | 6.25 |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.